 Hypertension erythropoietin therapy anemic hemodialysis patients Recombinant human erythropoietin rHuEpo anemia end-stage renal disease hypertension adverse effect red cell mass study patients rHuEpo increase mean arterial pressure mm Hg new additional hypertensive medications Retrospective analysis blood pressure pretreatment hematocrit level equal dependency red cell transfusions Factors hypertension rate rise hematocrit net rise hematocrit age sex number years dialysis presence absence kidneys smoking presence pretreatment hypertension Noninvasive hemodynamic studies normotensive patients improvement anemia normalization decreased peripheral vascular resistance reduction normal elevated cardiac output patients clinical hypertension Follow-up hemodynamic studies patients new additional antihypertensive medications difficult hypertension routine medication hypertensive encephalopathy blood pressure increases hematocrit rHuEpo therapy